| Abstract: | We introduce and demonstrate use of a novel, diffuse optical tomography (DOT) based breast cancersignature for monitoring progression of neoadjuvant chemotherapy. This signature, called probabilityof malignancy, is obtained by statistical image analysis of total hemoglobin concentration, bloodoxygen saturation, and scattering coefficient distributions in the breast tomograms of atraining-set population with biopsy-confirmed breast cancers. A pilot clinical investigation adaptsthis statistical image analysis approach for chemotherapy monitoring of three patients. Thoughpreliminary, the study shows how to use the malignancy parameter for separating responders frompartial-responders and demonstrates the potential utility of the methodology compared to traditionalDOT quantification schemes.OCIS codes: (170.3830) Mammography, (170.3880) Medical and biological imaging, (170.1610) Clinical applications, (170.6510) Spectroscopy, tissue diagnostics |
